PIK3CA and breast carcinoma: Our contention is that prior work assessing PI3K inhibition in breast cancer, including but not limited to Gedatolisib, predominantly gauged efficacy based on achieving stasis of orthotopically implanted primary tumors or of spontaneous tumors in genetically engineered mouse models [38, 40, 49].